FDA tracks Park gamma camera failure

Article

The perils of buying expensive capital medical equipment from companies in poor financial health were brought into focus last month after the Food and Drug Administration announced the failure of a gamma camera manufactured by Park Medical Systems, which

The perils of buying expensive capital medical equipment from companies in poor financial health were brought into focus last month after the Food and Drug Administration announced the failure of a gamma camera manufactured by Park Medical Systems, which went out of business last year.

According to the FDA, a stainless steel plate from a harmonic drive motor on an Isocam II camera failed, causing an arm of the dual-head system to fall into the gantry housing of the device. No collimator was on the camera at the time and no patient or operator was injured.

Adverse events such as the Isocam II failure are usually reported to the device manufacturer, but since Park filed for bankruptcy last year, the FDA is advising owners of Park systems to report any adverse events due to device malfunction to the agency itself. The FDA is also asking owners of Park systems to notify the agency so it can forward new information to Park users. The FDA's contact on the Park issue is Paula Simenauer, who can be reached by fax at 301/594-2968 or by e-mail at pzs@cdrh.fda.gov.

Park filed for bankruptcy in July after struggling to stay afloat for much of 1997 (SCAN 8/6/97), and the status of much of the company's installed base regarding service and maintenance issues is unknown. At least one Park facility, however, Cedars-Sinai Medical Center in Los Angeles, is using the multivendor service operations of ADAC Laboratories to maintain its system. Cedars-Sinai signed on with ADAC six months ago, according to a hospital spokesperson.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.